New combo therapy aims to tame rare brain disease with fewer steroids
NCT ID NCT07159893
First seen Oct 31, 2025 · Last updated May 13, 2026 · Updated 31 times
Summary
This study tests a new drug called inectolizumab combined with steroids in people newly diagnosed with neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease that attacks the nerves. The goal is to see if the drug can help control the disease while allowing patients to use lower doses of steroids, reducing side effects. The study will enroll 25 adults who have not yet received treatment for their first attack.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.